Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13013128 | 1.00 | CCR2 (0.59) | CCR2CA1CA2CA4ALDH1A1 | |
| SCHEMBL12788589 | 0.98 | CCR2 (0.58) | CCR2CA1CA2CA4ALDH1A1 | |
| SCHEMBL15199074 | 0.95 | CCR2 (0.57) | CCR2CA1CA2ALDH1A1KMT2A | |
| SCHEMBL13967161 | 0.89 | CCR2 (0.53) | CCR2CA1CA2ALDH1A1 | |
| SCHEMBL24565369 | 0.79 | HTT (0.46) | CCR2CA1CA2CA4KMT2A | |
| SCHEMBL6093270 | 0.79 | HTT (0.46) | CCR2CA1CA2CA4KMT2A | |
| SCHEMBL9932237 | 0.78 | GAA (0.50) | CCR2CA1CA2KMT2A | |
| SCHEMBL25981811 | 0.78 | GAA (0.50) | CCR2CA1CA2KMT2A | |
| SCHEMBL999679 | 0.78 | GAA (0.50) | CCR2CA1CA2KMT2A | |
| SCHEMBL2792237 | 0.77 | MCL1 (0.42) | CCR2CA1CA2CA4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324089-A1 | Anti-inflammatory composition | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100113518-A1 | METHODS OF USING ANTI-INFLAMMATORY COMPOUNDS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324089-A1 | Anti-inflammatory composition | TNF, IL1B, IL1A | CCR2 85/4885CA1 3707/4885CA2 2542/4885 |
| US-20100113518-A1 | METHODS OF USING ANTI-INFLAMMATORY COMPOUNDS | TNF, PTGES2, MMP8 | CCR2 133/4885CA1 1142/4885CA2 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.